Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 11/20 | 0.43 |
| ▸ | AURKA | O14965 | 6/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.39 |
| ▸ | JAK1 | P23458 | 4/20 | 0.38 |
| ▸ | BTK | Q06187 | 7/20 | 0.38 |
| ▸ | JAK2 | O60674 | 3/20 | 0.37 |
| ▸ | TYK2 | P29597 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12174884 | 0.92 | JAK3 (0.44) | JAK3AURKAAURKBJAK1BTK | |
| SCHEMBL14957676 | 0.89 | JAK1 (0.41) | JAK3AURKAAURKBJAK1JAK2 | |
| SCHEMBL14957925 | 0.83 | JAK3 (0.46) | JAK3JAK1BTKJAK2TYK2 | |
| SCHEMBL2586753 | 0.81 | JAK3 (0.42) | JAK3AURKBJAK1BTKJAK2 | |
| SCHEMBL2589717 | 0.80 | JAK3 (0.46) | JAK3JAK1BTKJAK2TYK2 | |
| SCHEMBL14957731 | 0.80 | JAK3 (0.44) | JAK3AURKAAURKBJAK1JAK2 | |
| SCHEMBL2582400 | 0.80 | JAK3 (0.43) | JAK3AURKBJAK1BTKJAK2 | |
| SCHEMBL14957590 | 0.79 | JAK1 (0.47) | JAK3AURKAJAK1JAK2TYK2 | |
| SCHEMBL14957723 | 0.79 | AURKA (0.44) | JAK3AURKAAURKBJAK1JAK2 | |
| SCHEMBL12174929 | 0.79 | JAK3 (0.40) | JAK3AURKAAURKBJAK1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130131043-A1 | PYRAZOLE COMPOUNDS AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2013-05-23 | — | — | US | claimed |
| US-20130131043-A1 | PYRAZOLE COMPOUNDS AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2013-05-23 | — | — | US | disclosed |
| US-20130131043-A1 | PYRAZOLE COMPOUNDS AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2013-05-23 | — | — | US | disclosed |
| US-20130131043-A1 | PYRAZOLE COMPOUNDS AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2013-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131043-A1 | PYRAZOLE COMPOUNDS AS JAK INHIBITORS | JAK1, JAK3, JAK2 | JAK3 2/4885AURKA 406/4885AURKB 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.